Mepolizumab: Phase III started

GlaxoSmithKline began the 24-week, double-blind, placebo-controlled, international Phase III MEA115575 trial to evaluate 100 mg subcutaneous mepolizumab every 4 weeks for up to 20 weeks plus an oral c...